Intest Res  
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
Taku Kobayashi1, Tadakazu Hisamatsu2, Yasuo Suzuki3, Haruhiko Ogata4, Akira Andoh5, Toshimitsu Araki6, Ryota Hokari7, Hideki Iijima8, Hiroki Ikeuchi9, Yoh Ishiguro10, Shingo Kato11, Reiko Kunisaki12, Takayuki Matsumoto13, Satoshi Motoya14, Masakazu Nagahori15, Shiro Nakamura16, Hiroshi Nakase17, Tomoyuki Tsujikawa18, Makoto Sasaki19, Kaoru Yokoyama20, Naoki Yoshimura21, Kenji Watanabe22, Miiko Katafuchi23, Mamoru Watanabe15, Toshifumi Hibi1
1Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, 2The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, 3Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, 4Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, 5Department of Gastroenterology, Shiga University of Medical Science, Otsu, 6Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, 8Department of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, Suita, 9Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College Of Medicine, Nishinomiya, 10Department of Gastroenterology and Hematology, Hirosaki National Hospital, Hirosaki, 11Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Kawagoe, 12Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Yokohama, 13Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, 14IBD Center, Sapporo-Kosei General Hospital, Sapporo, 15Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, 16 Department of Inflammatory Bowel Disease, Hyogo College Of Medicine, Nishinomiya, 17Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, 18Department of Gastroenterology and Hepatology, Higashi-Ohmi General Medical Center , Higashi-Ohmi, 19Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, 20Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, 21Division of Gastroenterology, Department of Medicine, Tokyo Yamate Medical Center, Tokyo, 22Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, 23Medical Affairs, Medical, AbbVie GK, Tokyo
Correspondence to: Tadakazu Hisamatsu, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka shi, Tokyo 181-8611, Japan. Tel: +81-422-47-5511, Fax: +81-422-71-5381, E-mail:
Received: July 15, 2017; Revised: September 22, 2017; Accepted: October 19, 2017; Published online: December 7, 2017.
© Korean Association for the Study of Intestinal Diseases. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
Keywords: Crohn disease; Colitis, ulcerative; Prognosis; Colorectal neoplasms; Consensus

This Article



Official Journal of

Indexed/Covered by